Prezel

Prezel

pregabalin

Manufacturer:

Ind-Swift
Concise Prescribing Info
Contents
Pregabalin

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Indications/Uses
Neuropathic pain including diabetic peripheral neuropathy & post-herpetic neuralgia in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisation. Generalised anxiety disorder (GAD) in adults. Fibromyalgia management.
Dosage/Direction for Use
150-600 mg daily in 2 or 3 divided doses. Neuropathic pain Initially 150 mg daily. May increase to 300 mg daily after an interval of 3-7 days to a max of 600 mg daily after an additional 7-day interval if needed. Epilepsy Initially 150 mg daily. May increase to 300 mg daily after 1 wk to a max of 600 mg after an additional wk. GAD 150-600 mg daily in 2 or 3 divided doses. Initially 150 mg daily, may increase to 300 mg daily after 1 wk. Following an additional wk, may increase to 450 mg daily to a max of 600 mg daily after an additional wk. Fibromyalgia 300-450 mg daily. Initially 75 mg bd, may increase to 150 mg bd w/in 1 wk based on efficacy & tolerability. Renal impairment CrCl ≥60 mL/min Initially 150 mg/day. Dose regimen: bd or tds. Max: 600 mg/day, ≥30-<60 mL/min Initially 75 mg/day. Dose regimen: bd or tds. Max: 300 mg/day, ≥15-<30 mL/min Initially 25-50 mg/day. Dose regimen: once daily or bd. Max: 150 mg/day, <15 mL/min Initially 25 mg/day. Dose regimen: once daily. Max: 75 mg/day. Supplementary dosage following haemodialysis Initially 25 mg/day as single dose. Max: 100 mg/day.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity.
MIMS Class
Drugs for Neuropathic Pain
ATC Classification
N02BF02 - pregabalin ; Belongs to the class of gabapentinoids. Used to relieve pain and other conditions.
Presentation/Packing
Form
Prezel cap 150 mg
Packing/Price
1's
Form
Prezel cap 75 mg
Packing/Price
1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement